刘美,刘梅林

• 1:北京大学第一医院老年病内科

摘要(Abstract)：

<正>2016年心血管领域公布了多个临床研究结果和指南的更新,为老年心血管疾病的诊治提供了参考和依据。以下对2016年老年心血管领域进展进行综述。1高血压领域老年患者的降压目标值仍然存在争议。基于2015年收缩期血压干预试验(SPRINT)结果[1],2016年加拿大高血压教育计划发布《高血压指南:血压的测量、诊断、风险评估、预

关键词(KeyWords)： 老年;心血管;高血压;冠心病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘美,刘梅林

参考文献(References)：

• [1]Wright JT Jr,Williamson JD,Whelton PK,et al.A Randomized Trial of Intensive versus Standard Blood-Pressure Control.N Engl J Med,2015,373(22):2103-2116.
• [2]Harris KC,Benoit G,Dionne J,et al.Hypertension Canada's2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement,Diagnosis,and Assessment of Risk of Pediatric Hypertension.Can J Cardiol,2016,32(5):589-597.
• [3]Yusuf S,Lonn E,Pais P,et al.Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.N Engl J Med,2016,374(21):2032-2043.
• [4]Vidal-Petiot E,Ford I,Greenlaw N,et al.Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease:an international cohort study.Lancet,2016,388(10056):2142-2152.
• [5]Piepoli MF,Hoes AW,Agewall S,et al.2016 European Guidelines on cardiovascular disease prevention in clinical practice:The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of10 societies and by invited experts):Developed with the special contribution of the European Association for Cardiovascular Prevention&Rehabilitation(EACPR).Eur J Prev Cardiol,2016,23(11):NP1-NP96.
• [6]Puri R,Nissen SE,Somaratne R,et al.Impact of PCSK9inhibition on coronary atheroma progression:Rationale and design of Global Assessment of Plaque Regression with a PCSK9Antibody as Measured by Intravascular Ultrasound(GLAGOV).Am Heart J,2016,176:83-92.
• [7]Law M,Rudnicka AR.Statin safety:a systematic review.Am J Cardiol,2006,97(8A):52C-60C.
• [8]Nissen SE,Stroes E,Dent-Acosta RE,et al.Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With MuscleRelated Statin Intolerance:The GAUSS-3 Randomized Clinical Trial.JAMA,2016,315(15):1580-1590.
• [9]Catapano AL,Graham I,De Backer G,et al.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.Eur Heart J,2016,37(39):2999-3058.
• [10]诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版).中国循环杂志,2016,31(10):15-35.
• [11]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Thorac Cardiovasc Surg,2016,152(5):1243-1275.
• [12]刘洁云,秦雷,王要鑫,等.年龄>75岁老年冠心病患者置入Bu MA支架后缩短氯吡格雷服药时间的短期安全性研究.中国介入心脏病杂志,2016,24(1):37-39.
• [13]Rich MW,Chyun DA,Skolnick AH,et al.Knowledge Gaps in Cardiovascular Care of the Older Adult Population:A Scientific Statement From the American Heart Association,American College of Cardiology,and American Geriatrics Society.J Am Coll Cardiol,2016,67(20):2419-2440.
• [14]杨新春.2016年欧州心脏病学会心房颤动管理指南解读.中国介入心脏病杂志,2016,24(11):623-628.
• [15]Mant J,Hobbs FD,Fletcher K,et al.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomised controlled trial.Lancet,2007,370(9586):493-503.
• [16]Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Eur Heart J,2016,37(38):2893-2962.
• [17]Paikin JS,Wright DS,Crowther MA,Mehta SR,Eikelboom JW.Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.Circulation,2010,121(18):2067-2070.
• [18]Gibson CM,Mehran R,Bode C,et al.Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.N Engl J Med,2016,375(25):2423-2434.
• [19]Olesen JB,Lip GY,Lindhardsen J,et al.Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation:A net clinical benefit analysis using a‘real world’nationwide cohort study.Thromb Haemost,2011,106(4):739-749.
• [20]Vardeny O,Claggett B,Packer M,et al.Efficacy of sacubitril/valsartan vs.enalapril at lower than target doses in heart failure with reduced ejection fraction:the PARADIGM-HF trial.Eur J Heart Fail,2016,18(10):1228-1234.
• [21]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC.Eur Heart J,2016,37(27):2129-2200.
• [22]Page RL,O'Bryant CL,Cheng D,et al.Drugs That May Cause or Exacerbate Heart Failure:A Scientific Statement From the American Heart Association.Circulation,2016,134(6):e32-69.
• [23]Mack MJ,Leon MB,Smith CR,et al.5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis(PARTNER 1):a randomised controlled trial.Lancet,2015,385(9986):2477-2484.
• [24]Kapadia SR,Leon MB,Makkar RR,et al.5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis(PARTNER1):a randomised controlled trial.Lancet,2015,385(9986):2485-2491.
• [25]Leon MB,Smith CR,Mack MJ,et al.Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.N Engl J Med,2016,374(17):1609-1620.
• [26]Lange R,Beckmann A,Neumann T,et al.Quality of Life After Transcatheter Aortic Valve Replacement:Prospective Data From GARY(German Aortic Valve Registry).JACC Cardiovasc Interv,2016,9(24):2541-2554.